专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US07858092B2 Neovascular-targeted immunoconjugates 有权
标题翻译：新生血管靶向免疫缀合物
公开(公告)号：US07858092B2
公开(公告)日：2010-12-28
申请号：US11134428
申请日：2005-05-23
申请人： Alan Garen , Zhiwei Hu
发明人： Alan Garen , Zhiwei Hu
IPC分类号： A61K39/00
CPC分类号： C07K16/18 , A61K2039/505 , C07K2317/622 , C07K2317/732 , C07K2319/30
摘要： Immunoconjugates for treating diseases associated with neovascularization such as cancer, rheumatoid arthritis, the exudative form of macular degeneration, and atherosclerosis are described. The immunoconjugates typically consist of the Fc region of a human IgG1 immunoglobulin including the hinge, or other effector domain or domains that can elicit, when administered to a patient, a cytolytic immune response or cytotoxic effect against a targeted cell. The effector domain is conjugated to a targeting domain which comprises a factor VII mutant that binds with high affinity and specificity to tissue factor but does not initiate blood clotting such as factor VII having a substitution of alanine for lysine-341 or of alanine for serine-344.
摘要翻译：描述了用于治疗与新生血管形成相关疾病如癌症，类风湿性关节炎，渗出性黄斑变性和动脉粥样硬化的免疫缀合物。免疫缀合物通常由包含铰链的人IgG1免疫球蛋白的Fc区组成，或者当向患者施用时可以引发针对靶细胞的细胞溶解免疫应答或细胞毒性作用的其它效应结构域或结构域。效应结构域与靶向结构域结合，该靶向结构域包含以组合因子的高亲和性和特异性结合但不引发血液凝固的因子VII突变体，例如具有丙氨酸取代赖氨酸341或丙氨酸的丝氨酸 - 344。

2. 发明授权

US08071104B2 Neovascular-targeted immunoconjugates 有权
标题翻译：新生血管靶向免疫缀合物
公开(公告)号：US08071104B2
公开(公告)日：2011-12-06
申请号：US12977937
申请日：2010-12-23
申请人： Alan Garen , Zhiwei Hu
发明人： Alan Garen , Zhiwei Hu
IPC分类号： A61K39/00
CPC分类号： C07K16/18 , A61K2039/505 , C07K2317/622 , C07K2317/732 , C07K2319/30
摘要： Immunoconjugates for treating diseases associated with neovascularization such as cancer, rheumatoid arthritis, the exudative form of macular degeneration, and atherosclerosis are described. The immunoconjugates typically consist of the Fc region of a human IgG1 immunoglobulin including the hinge, or other effector domain or domains that can elicit, when administered to a patient, a cytolytic immune response or cytotoxic effect against a targeted cell. The effector domain is conjugated to a targeting domain which comprises a factor VII mutant that binds with high affinity and specificity to tissue factor but does not initiate blood clotting such as factor VII having a substitution of alanine for lysine-341 or of alanine for serine-344.
摘要翻译：描述了用于治疗与新生血管形成相关疾病如癌症，类风湿性关节炎，渗出性黄斑变性和动脉粥样硬化的免疫缀合物。免疫缀合物通常由包含铰链的人IgG1免疫球蛋白的Fc区组成，或者当向患者施用时可以引发针对靶细胞的细胞溶解免疫应答或细胞毒性作用的其它效应结构域或结构域。效应结构域与靶向结构域结合，该靶向结构域包含以组合因子的高亲和性和特异性结合但不引发血液凝固的因子VII突变体，例如具有丙氨酸取代赖氨酸341或丙氨酸的丝氨酸 - 344。

3. 发明申请

US20050214298A1 Neovascular-targeted immunoconjugates 有权
标题翻译：新生血管靶向免疫缀合物
公开(公告)号：US20050214298A1
公开(公告)日：2005-09-29
申请号：US11134428
申请日：2005-05-23
申请人： Alan Garen , Zhiwei Hu
发明人： Alan Garen , Zhiwei Hu
IPC分类号： C07K16/18 , A61K48/00 , A61K39/395
CPC分类号： C07K16/18 , A61K2039/505 , C07K2317/622 , C07K2317/732 , C07K2319/30
摘要： Immunoconjugates for treating diseases associated with neovascularization such as cancer, rheumatoid arthritis, the exudative form of macular degeneration, and atherosclerosis are described. The immunoconjugates typically consist of the Fc region of a human IgG1 immunoglobulin including the hinge, or other effector domain or domains that can elicit, when administered to a patient, a cytolytic immune response or cytotoxic effect against a targeted cell. The effector domain is conjugated to a targeting domain which comprises a factor VII mutant that binds with high affinity and specificity to tissue factor but does not initiate blood clotting such as factor VII having a substitution of alanine for lysine-341 or of alanine for serine-344.
摘要翻译：描述了用于治疗与新生血管形成相关疾病如癌症，类风湿性关节炎，渗出性黄斑变性和动脉粥样硬化的免疫缀合物。免疫缀合物通常由包含铰链的人IgG1免疫球蛋白的Fc区组成，或者当向患者施用时可以引发针对靶细胞的细胞溶解免疫应答或细胞毒性作用的其它效应结构域或结构域。效应结构域与靶向结构域结合，该靶向结构域包含以组合因子的高亲和性和特异性结合但不引发血液凝固的因子VII突变体，例如具有丙氨酸取代赖氨酸341或丙氨酸的丝氨酸 - 344。

4. 发明申请

US20130073608A1 USER INFORMATION PUSHING METHOD, USER INFORMATION PRESENTATION METHOD, SYSTEM, SERVER AND CLIENT 审中-公开
标题翻译：用户信息推送方法，用户信息呈现方法，系统，服务器和客户端
公开(公告)号：US20130073608A1
公开(公告)日：2013-03-21
申请号：US13319921
申请日：2010-11-10
申请人： Zhiwei Hu , Lixia Liu , Zhang Chen , Jianjun Xiao , Xiaopeng Yuan , Kunhua Ye
发明人： Zhiwei Hu , Lixia Liu , Zhang Chen , Jianjun Xiao , Xiaopeng Yuan , Kunhua Ye
IPC分类号： G06F15/16
CPC分类号： H04L67/26 , H04M15/43 , H04M15/59 , H04M15/60 , H04M15/61 , H04M15/70 , H04M15/72 , H04M15/83 , H04M15/84 , H04M15/85 , H04M15/857 , H04W4/12
摘要： The invention discloses a user information pushing method, a user information representation method, a system, a server and a client. The pushing method includes: arranging a plurality of service interfaces to be invoked by the client, wherein the service interfaces comprise a real-time information pushing interface; receiving, by a server, through the real-time information pushing interface, a real-time information acquisition instruction sent by the client, when the client uses a target service and automatically invokes the real-time information pushing interface; acquiring real-time information of the target service according to a subscriber number contained in the real-time information acquisition instruction; and pushing the real-time information to the client. In the embodiments of the present invention, by means of the client, user may obtain in real time the user information pushed by the server and present the user information by means of the preset presentation interface while using a target service. Compared with the prior art, the user does not need to conduct manual query operations after finishing the target service, therefore the implementation performance for the client to output user information and user experience are improved.
摘要翻译：本发明公开了一种用户信息推送方法，用户信息表示方法，系统，服务器和客户端。推送方法包括：安排由客户端调用的多个服务接口，其中服务接口包括实时信息推送接口; 当客户端使用目标服务并自动调用实时信息推送接口时，由服务器通过实时信息推送接口接收由客户端发送的实时信息获取指令; 根据包含在实时信息获取指令中的用户号码，获取目标服务的实时信息; 并将实时信息推送给客户。在本发明的实施例中，通过客户端，用户可以实时获取由服务器推送的用户信息，并且在使用目标服务的同时通过预设的呈现界面呈现用户信息。与现有技术相比，用户在完成目标服务后不需要进行手动查询操作，因此提高了客户端输出用户信息和用户体验的实现性能。

5. 发明申请

US20120190113A1 Macroporous Microcarrier Specific to Liver Cell, Preparation Method and Use Thereof 审中-公开
标题翻译：特异于肝细胞的大孔微载体，其制备方法和用途
公开(公告)号：US20120190113A1
公开(公告)日：2012-07-26
申请号：US13389595
申请日：2010-04-17
申请人： Yi Gao , Mingxin Pan , Duhui Gong , Zhi Zhang , Huancheng Zhou , Zhiwei Hu
发明人： Yi Gao , Mingxin Pan , Duhui Gong , Zhi Zhang , Huancheng Zhou , Zhiwei Hu
IPC分类号： C12N5/071
CPC分类号： C08B37/003 , C08H1/00 , C08J3/12 , C08J9/0061 , C08J9/286 , C08J2389/00 , C08J2405/00 , C08L5/08 , C08L89/00 , C12N5/0075 , C12N5/067 , C12N2531/00 , C12N2533/50 , C12N2533/72 , C08L2666/26
摘要： The present invention provides a macroporous microcarrier specific to hepatocytes using silk fibroin and galactosylated chitosan as main raw material, a preparation method thereof, and application for hepatocyte culture under the culture condition of microgravity rotation. The macroporous microcarrier s a sphere prepared from silk fibroin and galactosylated chitosan under the effect of crosslinker, wherein based on the total weight of the sphere, the content of silk fibroin is 50-80 wt % and the content of galactosylated chitosan is 15-40 wt %. The diameter of the microcarrier is 200-500 μm, and the aperture of the microcarrier is 40-80 μm. Compared with normal solid scaffold material, the microcarrier provided by the present invention has larger surface area/volume ratio and, a sinus gap structure extremely similar with in-vivo liver sinus structure, therefore it is more conducive to adhering of the hepatocytes on the scaffold material, contacting between cells, transporting oxygen and nutrient components and excreting metabolic products.
摘要翻译：本发明提供使用丝素蛋白和半乳糖基化壳聚糖作为主要原料的肝细胞特异性的大孔微载体，其制备方法，以及微重力旋转培养条件下肝细胞培养的应用。由丝素蛋白和半乳糖基化壳聚糖制备的大孔微球体在交联剂的作用下，其中以球体总重为基准，丝素蛋白含量为50-80重量％，半乳糖基化壳聚糖含量为15-40重量％％。微载体的直径为200-500μm，微载体的孔径为40-80μm。与正常的固体支架材料相比，本发明提供的微载体具有较大的表面积/体积比，以及与体内肝窦结构非常相似的窦间隙结构，因此更有利于肝细胞在支架上的粘附材料，细胞之间的接触，运输氧气和营养成分并排出代谢产物。

6. 发明申请

US20120082686A1 Neovascular-Targeted Immunoconjugates 有权
标题翻译：新血管内靶向免疫缀合物
公开(公告)号：US20120082686A1
公开(公告)日：2012-04-05
申请号：US13290497
申请日：2011-11-07
申请人： Alan GAREN , Zhiwei HU
发明人： Alan GAREN , Zhiwei HU
IPC分类号： A61K39/44 , A61P35/04 , A61P29/00 , A61P9/10 , A61P27/02 , A61P35/00
CPC分类号： C07K16/18 , A61K2039/505 , C07K2317/622 , C07K2317/732 , C07K2319/30
摘要： Immunoconjugates for treating diseases associated with neovascularization such as cancer, rheumatoid arthritis, the exudative form of macular degeneration, and atherosclerosis are described. The immunoconjugates typically consist of the Fc region of a human IgG1 immunoglobulin including the hinge, or other effector domain or domains that can elicit, when administered to a patient, a cytolytic immune response or cytotoxic effect against a targeted cell. The effector domain is conjugated to a targeting domain which comprises a factor VII mutant that binds with high affinity and specificity to tissue factor but does not initiate blood clotting such as factor VII having a substitution of alanine for lysine-341 or of alanine for serine-344.
摘要翻译：描述了用于治疗与新生血管形成相关疾病如癌症，类风湿性关节炎，渗出性黄斑变性和动脉粥样硬化的免疫缀合物。免疫缀合物通常由包含铰链的人IgG1免疫球蛋白的Fc区组成，或者当向患者施用时可以引发针对靶细胞的细胞溶解免疫应答或细胞毒性作用的其它效应结构域或结构域。效应结构域与靶向结构域结合，该靶向结构域包含以组合因子的高亲和性和特异性结合但不引发血液凝固的因子VII突变体，例如具有丙氨酸取代赖氨酸341或丙氨酸的丝氨酸 - 344。

7. 发明授权

US06924359B1 Neovascular-targeted immunoconjugates 有权
公开(公告)号：US06924359B1
公开(公告)日：2005-08-02
申请号：US10030203
申请日：2000-06-14
申请人： Alan Garen , Zhiwei Hu
发明人： Alan Garen , Zhiwei Hu
IPC分类号： C07K16/18 , C07K16/00 , C12N15/00
CPC分类号： C07K16/18 , A61K2039/505 , C07K2317/622 , C07K2317/732 , C07K2319/30
摘要： Immunoconjugates for treating diseases associated with neovascularization such as cancer, rheumatoid arthritis, the exudative form of macular degeneration, and atherosclerosis are described. The immunoconjugates typically consist of the Fc region of a human IgG1 immunoglobulin including the hinge, or other effector domain or domains that can elicit, when administered to a patient, a cytolytic immune response or cytotoxic effect against a targeted cell. The effector domain is conjugated to a targeting domain which comprises a factor VII mutant that binds with high affinity and specificity to tissue factor but does not initiate blood clotting such as factor VII having a substitution of alanine for lysine-341 or of alanine for serine-344.

8. 发明授权

US08388974B2 Neovascular-targeted immunoconjugates 有权
标题翻译：新生血管靶向免疫缀合物
公开(公告)号：US08388974B2
公开(公告)日：2013-03-05
申请号：US13290497
申请日：2011-11-07
申请人： Alan Garen , Zhiwei Hu
发明人： Alan Garen , Zhiwei Hu
IPC分类号： A61K39/00
CPC分类号： C07K16/18 , A61K2039/505 , C07K2317/622 , C07K2317/732 , C07K2319/30
摘要： Immunoconjugates for treating diseases associated with neovascularization such as cancer, rheumatoid arthritis, the exudative form of macular degeneration, and atherosclerosis are described. The immunoconjugates typically consist of the Fc region of a human IgG1 immunoglobulin including the hinge, or other effector domain or domains that can elicit, when administered to a patient, a cytolytic immune response or cytotoxic effect against a targeted cell. The effector domain is conjugated to a targeting domain which comprises a factor VII mutant that binds with high affinity and specificity to tissue factor but does not initiate blood clotting such as factor VII having a substitution of alanine for lysine-341 or of alanine for serine-344.
摘要翻译：描述了用于治疗与新生血管形成相关疾病如癌症，类风湿性关节炎，渗出性黄斑变性和动脉粥样硬化的免疫缀合物。免疫缀合物通常由包含铰链的人IgG1免疫球蛋白的Fc区组成，或者当向患者施用时可以引发针对靶细胞的细胞溶解免疫应答或细胞毒性作用的其它效应结构域或结构域。效应结构域与靶向结构域结合，该靶向结构域包含以组合因子的高亲和性和特异性结合但不引发血液凝固的因子VII突变体，例如具有丙氨酸取代赖氨酸341或丙氨酸的丝氨酸 - 344。

9. 发明申请

US20110117114A1 Neovascular-Targeted Immunoconjugates 有权
标题翻译：新血管内靶向免疫缀合物
公开(公告)号：US20110117114A1
公开(公告)日：2011-05-19
申请号：US12977937
申请日：2010-12-23
申请人： Alan GAREN , Zhiwei HU
发明人： Alan GAREN , Zhiwei HU
IPC分类号： A61K39/395 , A61P29/00 , A61P35/00
CPC分类号： C07K16/18 , A61K2039/505 , C07K2317/622 , C07K2317/732 , C07K2319/30
摘要： Immunoconjugates for treating diseases associated with neovascularization such as cancer, rheumatoid arthritis, the exudative form of macular degeneration, and atherosclerosis are described. The immunoconjugates typically consist of the Fc region of a human IgG1 immunoglobulin including the hinge, or other effector domain or domains that can elicit, when administered to a patient, a cytolytic immune response or cytotoxic effect against a targeted cell. The effector domain is conjugated to a targeting domain which comprises a factor VII mutant that binds with high affinity and specificity to tissue factor but does not initiate blood clotting such as factor VII having a substitution of alanine for lysine-341 or of alanine for serine-344.
摘要翻译：描述了用于治疗与新生血管形成相关疾病如癌症，类风湿性关节炎，渗出性黄斑变性和动脉粥样硬化的免疫缀合物。免疫缀合物通常由人IgG1免疫球蛋白的Fc区组成，包括铰链，或当向患者施用时可以引发针对靶细胞的溶细胞免疫应答或细胞毒性作用的其他效应结构域或结构域。效应结构域与靶向结构域结合，该靶向结构域包含以组合因子的高亲和性和特异性结合但不引发血液凝固的因子VII突变体，例如具有丙氨酸取代赖氨酸341或丙氨酸的丝氨酸 - 344。

10. 发明授权

US07887809B1 Neovascular-targeted immunoconjugates 有权
公开(公告)号：US07887809B1
公开(公告)日：2011-02-15
申请号：US11925007
申请日：2007-10-26
申请人： Alan Garen , Zhiwei Hu
发明人： Alan Garen , Zhiwei Hu
IPC分类号： A61K39/00
CPC分类号： C07K16/18 , A61K2039/505 , C07K2317/622 , C07K2317/732 , C07K2319/30
摘要： Immunoconjugates for treating diseases associated with neovascularization such as cancer, rheumatoid arthritis, the exudative form of macular degeneration, and atherosclerosis are described. The immunoconjugates typically consist of the Fc region of a human IgG1 immunoglobulin including the hinge, or other effector domain or domains that can elicit, when administered to a patient, a cytolytic immune response or cytotoxic effect against a targeted cell. The effector domain is conjugated to a targeting domain which comprises a factor VII mutant that binds with high affinity and specificity to tissue factor but does not initiate blood clotting such as factor VII having a substitution of alanine for lysine-341 or of alanine for serine-344.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式